166 related articles for article (PubMed ID: 12364468)
21. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.
Renlund N; O'Neill FH; Zhang L; Sidis Y; Teixeira J
J Endocrinol; 2007 Oct; 195(1):95-103. PubMed ID: 17911401
[TBL] [Abstract][Full Text] [Related]
22. Activation of the activin A-ALK-Smad pathway in systemic sclerosis.
Takagi K; Kawaguchi Y; Kawamoto M; Ota Y; Tochimoto A; Gono T; Katsumata Y; Takagi M; Hara M; Yamanaka H
J Autoimmun; 2011 May; 36(3-4):181-8. PubMed ID: 21377836
[TBL] [Abstract][Full Text] [Related]
23. Cell-type specific regulation of myostatin signaling.
Kemaladewi DU; de Gorter DJ; Aartsma-Rus A; van Ommen GJ; ten Dijke P; 't Hoen PA; Hoogaars WM
FASEB J; 2012 Apr; 26(4):1462-72. PubMed ID: 22202673
[TBL] [Abstract][Full Text] [Related]
24. Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes.
Sarkar DK; Pastorcic M; De A; Engel M; Moses H; Ghasemzadeh MB
Endocrinology; 1998 Aug; 139(8):3620-8. PubMed ID: 9681516
[TBL] [Abstract][Full Text] [Related]
25. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3.
Takumi T; Moustakas A; Lin HY; Lodish HF
Exp Cell Res; 1995 Jan; 216(1):208-14. PubMed ID: 7813622
[TBL] [Abstract][Full Text] [Related]
27. Activin A induces neuronal differentiation and survival via ALK4 in a SMAD-independent manner in a subpopulation of human neuroblastomas.
Suzuki K; Kobayashi T; Funatsu O; Morita A; Ikekita M
Biochem Biophys Res Commun; 2010 Apr; 394(3):639-45. PubMed ID: 20226172
[TBL] [Abstract][Full Text] [Related]
28. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
Rejon CA; Hancock MA; Li YN; Thompson TB; Hébert TE; Bernard DJ
Cell Signal; 2013 Dec; 25(12):2717-26. PubMed ID: 24018044
[TBL] [Abstract][Full Text] [Related]
29. ALK4-SMAD2/3-SMAD4 signaling mediates the activin A-induced suppression of PTX3 in human granulosa-lutein cells.
Liu C; Chang HM; Yi Y; Fang Y; Zhao F; Leung PCK; Yang X
Mol Cell Endocrinol; 2019 Aug; 493():110485. PubMed ID: 31185247
[TBL] [Abstract][Full Text] [Related]
30. Blockade of ALK4/5 signaling suppresses cadmium- and erastin-induced cell death in renal proximal tubular epithelial cells via distinct signaling mechanisms.
Fujiki K; Inamura H; Sugaya T; Matsuoka M
Cell Death Differ; 2019 Nov; 26(11):2371-2385. PubMed ID: 30804470
[TBL] [Abstract][Full Text] [Related]
31. Cell-specificity of transforming growth factor-beta response is dictated by receptor bioavailability.
Suszko MI; Woodruff TK
J Mol Endocrinol; 2006 Jun; 36(3):591-600. PubMed ID: 16720726
[TBL] [Abstract][Full Text] [Related]
32. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
33. The crucial role of activin A/ALK4 pathway in the pathogenesis of Ang-II-induced atrial fibrosis and vulnerability to atrial fibrillation.
Wang Q; Yu Y; Zhang P; Chen Y; Li C; Chen J; Wang Y; Li Y
Basic Res Cardiol; 2017 Jul; 112(4):47. PubMed ID: 28639003
[TBL] [Abstract][Full Text] [Related]
34. New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration.
Pasteuning-Vuhman S; Boertje-van der Meulen JW; van Putten M; Overzier M; Ten Dijke P; Kiełbasa SM; Arindrarto W; Wolterbeek R; Lezhnina KV; Ozerov IV; Aliper AM; Hoogaars WM; Aartsma-Rus A; Loomans CJ
FASEB J; 2017 Jan; 31(1):238-255. PubMed ID: 27733450
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor-alpha and -beta are potent and effective inhibitors of GH4 pituitary tumor cell proliferation.
Ramsdell JS
Endocrinology; 1991 Apr; 128(4):1981-90. PubMed ID: 2004614
[TBL] [Abstract][Full Text] [Related]
36. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
Muenster U; Harrison CA; Donaldson C; Vale W; Fischer WH
J Biol Chem; 2005 Nov; 280(44):36626-32. PubMed ID: 16129674
[TBL] [Abstract][Full Text] [Related]
37. Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors.
D'Abronzo FH; Swearingen B; Klibanski A; Alexander JM
J Clin Endocrinol Metab; 1999 May; 84(5):1716-21. PubMed ID: 10323406
[TBL] [Abstract][Full Text] [Related]
38. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin.
Delbaere A; Sidis Y; Schneyer AL
Endocrinology; 1999 Jun; 140(6):2463-70. PubMed ID: 10342830
[TBL] [Abstract][Full Text] [Related]
39. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM
Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738
[TBL] [Abstract][Full Text] [Related]
40. Activin A induction of murine and ovine follicle-stimulating hormone β transcription is SMAD-dependent and TAK1 (MAP3K7)/p38 MAPK-independent in gonadotrope-like cells.
Wang Y; Bernard DJ
Cell Signal; 2012 Aug; 24(8):1632-40. PubMed ID: 22549017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
